Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- PMSB Proposes NDA Dossier Guide According to CTD
May 14, 2001
- BUSINESS NEWS IN BRIEF -1-
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
May 7, 2001
- BUSINESS NEWS IN BRIEF -2-
May 7, 2001
- Takeda Discovers Respiratory Disease-related Genes
May 7, 2001
- Only 2 out of 20 Keidanren Deregulation Proposals Implemented
May 7, 2001
- Short-acting Insulin Analog Treatment Effective in Type 2 Diabetes: JDA/Lilly Seminar
May 7, 2001
- 27 GEs Delisted 1 Year after Application of GE Rule
May 7, 2001
- Many Psychiatrists Dissatisfied with Drugs to Treat Schizophrenia
May 7, 2001
- CSTP Subpanel to Propose Promotion Strategy in Prioritized Fields
May 7, 2001
- OTC NEWS IN BRIEF
May 7, 2001
- PMSB Asks Manufacturers to Stop Supply of Phenacetin
May 7, 2001
- AstraZeneca's Diprivan Inj-Kit to Contribute to Preventing Accidents
May 7, 2001
- REGULATORY NEWS IN BRIEF
May 7, 2001
- Atorvastatin Raises Treatment Target Achievement Rates: Yamanouchi/Pfizer Seminar
May 7, 2001
- Japanese Global Strategy Update (1)
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
May 7, 2001
- Pricing Rule for Innovative Medical Devices to Be Studied
May 7, 2001
- DIAGNOSTIC NEWS IN BRIEF
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -3-
May 7, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…